Physician profile
Mark C Glotkowski
NPI 1821398660
$9,488.86
in general payments reported to CMS, 2019-2025
14 companies · $7,826 in 2025
The $7,826 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $478 · 2023: $579 · 2024: $606 · 2025: $7,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,000 · Food and Beverage: $2,108 · Travel and Lodging: $865 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,000.00 |
| Food and Beverage | $2,107.65 |
| Travel and Lodging | $864.94 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $7,506.98 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $537.00 | 2022-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Alkermes, INC. | $315.49 | 2023-2025 | Lybalvi, Aristada |
| Janssen Pharmaceuticals, INC | $282.01 | 2022-2025 | Invega Sustenna |
| Lundbeck LLC | $272.10 | 2023-2025 | Rexulti |
| Indivior INC. | $181.25 | 2023-2024 | Perseris |
| Neurocrine Biosciences, INC. | $157.41 | 2022-2025 | Ingrezza |
| Abbvie INC. | $75.44 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.61 | 2022-2023 | |
| Vanda Pharmaceuticals INC. | $44.30 | 2024-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $16.38 | 2025 | Uzedy |
| Noven Therapeutics, LLC | $14.78 | 2024 | Secuado |
| Corium, LLC | $12.77 | 2024 | Azstarys |
| Avanir Pharmaceuticals, INC. | $12.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Glotkowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.